Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | HTR1A | P08908 | 6/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 6/20 | 0.39 |
| ▸ | SLC6A4 | P31645 | 6/20 | 0.39 |
| ▸ | SLC6A3 | Q01959 | 3/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.37 |
| ▸ | DRD1 | P21728 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20292259 | 0.87 | HTR1A (0.55) | HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL629415 | 0.85 | ESR2 (0.44) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL13770265 | 0.84 | PDK2 (0.39) | PDK2 | |
| SCHEMBL4004744 | 0.80 | RBP4 (0.43) | — | |
| SCHEMBL628720 | 0.80 | PDE10A (0.43) | PDK2DRD2DRD1 | |
| SCHEMBL363270 | 0.76 | PDK2 (0.47) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL25400549 | 0.74 | PDK2 (0.46) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15354765 | 0.74 | PDK2 (0.46) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2642386 | 0.74 | PDK2 (0.46) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL934667 | 0.74 | PDK2 (0.46) | PDK2HTR1ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2935239-B1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI SA (FR) | 2018-08-29 | — | — | EP | disclosed |
| US-9611250-B2 | Process for preparing 4-(cyclopropylmethoxy)-N-(3,5-dichloro-1-oxido-4-pyridyl)-5-methoxypyridine-2-carboxamide | SANOFI (FR) | 2017-04-04 | — | — | US | disclosed |
| US-20150307474-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI (FR) | 2015-10-29 | — | — | US | disclosed |
| EP-2935239-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI (FR) | 2015-10-28 | — | — | EP | disclosed |
| WO-2014083106-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | SANOFI (FR) | 2014-06-05 | — | — | WO | disclosed |
| US-7687502-B2 | Substituted quinazoline or pyridopyrimidine derivative | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-03-30 | — | — | US | disclosed |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | MSD K.K. (JP) | 2008-02-07 | — | — | US | disclosed |
| EP-1734040-A1 | SUBSTITUTED QUINAZOLINE OR PYRIDOPYRIMIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-12-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150307474-A1 | PROCESS FOR PREPARING 4-(CYCLOPROPYLMETHOXY)-N-(3,5-DICHLORO-1-OXIDO-4-PYRIDYL)-5-METHOXYPYRIDINE-2-CARBOXAMIDE | CYP3A4, CYP4B1, CYP3A5 | PDK2 530/4885HTR1A 243/4885SLC6A2 2047/4885 |
| US-20080032996-A1 | Substituted Quinazoline or Pyridopyrimidine Derivative | GCK, GCKR, PDXK | PDK2 15/4885HTR1A 2175/4885SLC6A2 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.